Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IKNANASDAQ:IMRXNASDAQ:OKYONASDAQ:UPXI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIKNAIkena Oncology$1.34-0.7%$1.16$0.97▼$1.94$64.67M0.47141,197 shs74,305 shsIMRXImmuneering$1.96$1.41$1.00▼$3.83$70.53M-0.222.34 million shs179,827 shsOKYOOKYO Pharma$1.88+0.5%$1.43$0.81▼$1.98$63.61M-0.38131,674 shs45,403 shsUPXIUpexi$11.23+2.6%$7.97$1.90▼$22.57$425.79M-0.27863,242 shs244,304 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIKNAIkena Oncology+5.47%+14.89%+8.00%0.00%-24.16%IMRXImmuneering+4.81%+19.51%+58.06%+30.67%+42.03%OKYOOKYO Pharma+6.86%+6.86%+37.25%+34.53%+30.77%UPXIUpexi-3.78%+10.27%-22.17%+339.76%+1.54%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIKNAIkena Oncology3.01 of 5 stars3.35.00.00.01.41.71.3IMRXImmuneering3.87 of 5 stars3.35.00.00.03.43.31.3OKYOOKYO Pharma2.5511 of 5 stars3.55.00.00.01.51.70.0UPXIUpexi1.6898 of 5 stars0.05.00.00.02.53.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIKNAIkena Oncology 2.50Moderate Buy$3.00123.88% UpsideIMRXImmuneering 2.50Moderate Buy$15.33682.31% UpsideOKYOOKYO Pharma 3.00Buy$7.00272.34% UpsideUPXIUpexi 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest UPXI, IMRX, OKYO, and IKNA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2025IMRXImmuneeringOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$25.00 ➝ $21.005/6/2025IMRXImmuneeringChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.005/5/2025OKYOOKYO PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.004/10/2025IMRXImmuneeringNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.003/24/2025IMRXImmuneeringChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.003/21/2025IMRXImmuneeringNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00(Data available from 6/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIKNAIkena Oncology$659K98.13N/AN/A$3.52 per share0.38IMRXImmuneering$320K220.41N/AN/A$3.09 per share0.63OKYOOKYO PharmaN/AN/AN/AN/A($0.20) per shareN/AUPXIUpexi$16.56M25.71N/AN/A$2.85 per share3.94Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIKNAIkena Oncology-$68.17M-$0.86N/AN/AN/AN/A-36.88%-33.08%8/14/2025 (Estimated)IMRXImmuneering-$53.47M-$1.96N/AN/AN/AN/A-79.19%-69.08%8/5/2025 (Estimated)OKYOOKYO Pharma-$16.83MN/A0.00N/AN/AN/AN/AN/AN/AUPXIUpexi-$23.66MN/A0.00∞N/AN/AN/AN/A7/8/2025 (Estimated)Latest UPXI, IMRX, OKYO, and IKNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/16/2025Q1 2025UPXIUpexiN/A-$2.87N/A-$2.87N/A$3.16 million5/8/2025Q1 2025IKNAIkena Oncology-$0.21-$0.18+$0.03-$0.18N/AN/A5/5/2025Q1 2025IMRXImmuneering-$0.41-$0.42-$0.01-$0.42N/AN/A3/20/2025Q4 2024IMRXImmuneering-$0.42-$0.58-$0.16-$0.58N/AN/A3/11/2025Q4 2024IKNAIkena Oncology-$0.23-$0.18+$0.05-$0.19N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIKNAIkena OncologyN/AN/AN/AN/AN/AIMRXImmuneeringN/AN/AN/AN/AN/AOKYOOKYO PharmaN/AN/AN/AN/AN/AUPXIUpexiN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIKNAIkena OncologyN/A15.3215.32IMRXImmuneeringN/A7.997.99OKYOOKYO PharmaN/A0.28N/AUPXIUpexi0.350.580.53Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIKNAIkena Oncology75.00%IMRXImmuneering67.65%OKYOOKYO Pharma2.97%UPXIUpexi5.68%Insider OwnershipCompanyInsider OwnershipIKNAIkena Oncology5.94%IMRXImmuneering25.00%OKYOOKYO Pharma40.46%UPXIUpexi31.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIKNAIkena Oncology7048.26 million45.39 millionNot OptionableIMRXImmuneering6035.99 million23.29 millionNot OptionableOKYOOKYO Pharma733.84 million20.15 millionNot OptionableUPXIUpexi13037.92 million863,000OptionableUPXI, IMRX, OKYO, and IKNA HeadlinesRecent News About These CompaniesWall Street Zen Upgrades Upexi (NASDAQ:UPXI) to HoldJune 2 at 12:31 AM | marketbeat.comUpexi (NASDAQ:UPXI) Raised to Hold at Wall Street ZenJune 1 at 1:33 AM | americanbankingnews.comUpexi, Inc. (NASDAQ:UPXI) Short Interest UpdateMay 31, 2025 | marketbeat.comUpexi, Inc. (NASDAQ:UPXI) Sees Significant Drop in Short InterestMay 31, 2025 | americanbankingnews.comUpexi to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference on June 24-25May 30, 2025 | globenewswire.comUpexi releases presentation detailing Solana treasury strategyMay 29, 2025 | finance.yahoo.comUpexi Partners with Crypto-Native Marketing and Design Firm, GMI Digital, to Drive Solana-Focused StrategyMay 29, 2025 | globenewswire.comUpexi, Inc. Acquires 77,879 Locked SOL for $11.8 Million, Increasing Holdings to 679,677 SOLMay 28, 2025 | quiverquant.comUpexi, Inc. Buys Additional Locked SOL at a Discount for $11.8 millionMay 28, 2025 | taiwannews.com.twUpexi, Inc. Buys Additional Locked SOL at a Discount for $11.8 millionMay 28, 2025 | globenewswire.comUpexi Releases Investor Presentation Detailing Solana Treasury StrategyMay 27, 2025 | accessnewswire.comUpexi Inc.May 26, 2025 | wsj.comUpexi Appoints Brian Rudick, CFA as Chief Strategy OfficerMay 22, 2025 | accessnewswire.comUpexi Reports First Quarter 2025 Financial Results and Provides Update on Solana Treasury StrategyMay 16, 2025 | accessnewswire.comUpexi Buys Discounted Locked SOL, Surpasses $100 Million of SOL and Becomes the Largest Publicly-Traded Solana Treasury CompanyMay 12, 2025 | finanznachrichten.deUpexi Increases Solana Treasury to 201,500 Solana Tokens for $30 Million and Begins to Generate Staking RevenueMay 6, 2025 | finanznachrichten.deClassover Bets On Solana To Reshape Its Balance Sheet, Financial Strategy – Stock Continues Rally With 70% Pre-Market JumpMay 2, 2025 | msn.comThis is Why Companies are Diversifying with Cryptocurrencies, Like BitcoinApril 30, 2025 | baystreet.caCORRECTION FROM SOURCE: Upexi Purchases 45,733 Solana Tokens as it Begins Deploying $100 Million Treasury in Solana StrategyApril 29, 2025 | finanznachrichten.deUpexi Purchases 45,733 Solana Tokens as it Begins Deploying $100 Million Treasury in Solana StrategyApril 29, 2025 | finance.yahoo.comInsider Buying: Upexi, Inc. (NASDAQ:UPXI) CFO Purchases 43,860 Shares of StockApril 26, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeUPXI, IMRX, OKYO, and IKNA Company DescriptionsIkena Oncology NASDAQ:IKNA$1.34 -0.01 (-0.74%) As of 04:00 PM EasternIkena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.Immuneering NASDAQ:IMRX$1.96 0.00 (0.00%) As of 04:00 PM EasternImmuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.OKYO Pharma NASDAQ:OKYO$1.88 +0.01 (+0.53%) As of 03:59 PM EasternOKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.Upexi NASDAQ:UPXI$11.23 +0.28 (+2.56%) As of 04:00 PM EasternUpexi, Inc. manufactures and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc. and changed its name to Upexi, Inc. in August 2022. The company was incorporated in 2018 and is headquartered in Clearwater, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Robinhood Stock Keeps Giving Investors Reasons To Buy CrowdStrike Stock Dips on Guidance Miss: It May Rebound Fast Guidewire Rockets Higher: A Move Above $300 Is Probable TSMC Joins NVIDIA in UAE Push, Fueling Growth Outlook Intuit's AI Boom: Stock Soaring, But Should Investors Hit Pause? Constellation Energy and Meta Strike Nuclear Deal, Shares Whipsaw Archer's Midnight Air Taxi Soars, But Stock Doesn’t Budge Analog Devices' Cyclical Recovery Story Has Just Begun Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
